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Abstract
Objectives Glioblastoma (GBM) is highly proliferative, infiltrative, malignant
and the most deadly form of brain tumour. The epidermal growth factor receptor
(EGFR) is overexpressed, amplified and mutated in GBM and has been shown to
play key and important roles in the proliferation, growth and survival of this
tumour. The goal of our study was to investigate the antiproliferative, apoptotic
and molecular effects of apigenin in GBM.
Methods Proliferation and viability tests were carried out using the trypan blue
exclusion, MTT and lactate dehydrogenase (LDH) assays. Flow cytometry was
used to examine the effects of apigenin on the cell cycle check-points. In addi-
tion, we determined the effects of apigenin on EGFR-mediated signalling path-
ways by Western blot analyses.
Key findings Our results showed that apigenin reduced cell viability and prolif-
eration in a dose- and time-dependent manner while increasing cytotoxicity in
GBM cells. Treatment with apigenin-induced is poly ADP-ribose polymerase
(PARP) cleavage and caused cell cycle arrest at the G2M checkpoint. Further-
more, our data revealed that apigenin inhibited EGFR-mediated phosphorylation
of mitogen-activated protein kinase (MAPK), AKT and mammalian target of
rapamycin (mTOR) signalling pathways and attenuated the expression of Bcl-xL.
Conclusion Our results demonstrated that apigenin has potent inhibitory effects
on pathways involved in GBM proliferation and survival and could potentially be
used as a therapeutic agent for GBM.
Introduction
Glioblastoma (GBM) is a highly proliferative, infiltrative
brain tumour that is resistant to currently available
chemotherapy- and radiation-induced apoptotic tumour
cell death.[1,2] It is classified by the World Health Organiza-
tion (WHO) as a grade IV tumour,[3] and about fifteen per
cent of all primary brain tumours are GBM.[4] The majority
of those diagnosed with glioblastoma will die within a year
of diagnosis.[3] It is also a heterogeneous tumour; meaning
that each cell within the tumour may express distinct char-
acteristics.[5] Such distinct characteristics include, among
others, mutations and overexpression of certain proteins.
Epidermal growth factor receptor (EGFR) is one of the
proteins altered in GBM leading to a highly proliferative
and treatment-resistant tumour.[1–3,6] In particular, EGFR
may play a key role in the pathogenesis of GBM, as lower
grade gliomas do not have the EGFR overexpression that
GBM commonly present with.[6] EGFR signalling is
involved in multiple signal transduction pathways, most
notable of which involves activation of both the RAS/
MAPK and PI3K-AKT pathways, which provide key regula-
tion of cell growth, proliferation and survival.[7]
Beyond this role, EGFR signalling also modulates
tumour invasiveness by upregulating genes that code
for matrix metalloproteinase (MMP). MMP plays a role
in cell proliferation and migration when activated.[5]
Characteristically, GBM is an incredibly invasive type of
cancer, and EGFR overexpression may be involved in
creating this key trait.[6] Because of its importance to
tumour regulation, EGFR pathways remain an attractive
target in many types of cancer, including GBM, in spite
of the fact that current EGFR targeted therapies have
failed.[7]
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Mitogen-activated protein kinase (MAPK) and extracel-
lular signal-regulated kinase (ERK) are both regulatory
kinases important for cell proliferation through the modu-
lation of the cell cycle.[5,7] Inhibition of these kinases could
contribute to a halt of the cell growth cycle and in turn, the
inhibition of growth of cancer cells. The MAPK family
includes three different groups: ERK/MAPK, p38 and Jun
N-terminus kinase (JNK).[8] The most studied part of the
MAPK family is the ERK/MAPK portion, the activity of
which is regulated by a variety of growth factors and mito-
gens.[8]
Protein kinase B (AKT) is another important part of cell
signalling within tumour cells.[7] Mammalian target of
rapamycin (mTOR) is a signalling molecule further down-
stream of the AKT pathway. mTOR has recently been
shown to promote cancer cell growth and survival through
AKT activation, an effect which adds to treatment resis-
tance arising from the AKT pathway.[9] The positive effects
of mTOR on cancer cell survival, proliferation and malig-
nancy are mediated although the activation of S6 Kinase
(S6K) and the ability of S6K to increase the synthesis of
protective and metabolic proteins.[10]
Another key biological feature characteristic of glioblas-
toma is decreased cell death (apoptosis, which is commonly
referred to as programmed cell death). Apoptotic signalling
is a vital component of our body’s regulation of cell health
by inducing the destruction of harmful cells.[11] The pro-
cess of apoptosis is triggered by the activation of signalling
cascades that involve the cleavage of procaspases into
matured active caspases.[11] Initiator caspases upstream
become activated by protein cleavage performed by active
caspases, causing a downstream activation of executioner
caspases. The executioner caspases in turn cleave and either
destroy antiapoptotic protein or activate pro-apoptotic
protein. The antiapoptotic protein is poly ADP-ribose
polymerase (PARP).[12] This enzyme detects, binds to, and
repairs sites of DNA damage.[13–15] When caspases are acti-
vated, they bind and cleave PARP thereby preventing DNA
repair and inducing apoptotic cell death. For this reason,
PARP serves as a marker of apoptosis.[14,15] While PARP
executes its antiapoptotic effects by repairing DNA damage
and promoting cell growth, BCL-xL is another antiapop-
totic protein that is targeted, cleaved and destroyed by cas-
pases. BCL-xL inhibits apoptosis and promotes cell survival
through the protection of cellular mitochondria and the
prevention of the release of the caspase activating cyto-
chrome C.[14,15]
Malignant gliomas are resistant to chemotherapy and
radiation, and there is the need for the development of
other small molecule inhibitors that can be used in the
management of patients with glioma. Natural products pre-
sent a vast array of chemicals that can be investigated for
their potential therapeutic benefits. Flavonoids are natural
compounds found in many plants and vegetables. They
have been shown to possess a range of effects on biological
systems.[16,17] Apigenin (Figure 1) belongs to the flavone
subclass of flavonoids. Apigenin has shown promising
effects in the treatment of various cancers.[18–23] Apigenin
has demonstrated suppression of cancer signalling path-
ways and tumour cell adhesion on endothelial cells. Sig-
nalling pathways thought to be involved include JNK, ERK
and AP-1.[24] In other research studies, apigenin has exhib-
ited anti-inflammatory effects and demonstrated benefit in
metabolic syndrome via inhibition of the enzyme
NAD+ase.[17,25] Most relevant to this study, apigenin has
demonstrated induction of apoptosis of certain cancer
cells.[18–23]
The biological effects of apigenin on the survival, prolif-
eration and EGFR-mediated GBM growth is not well-
understood. The goal of this study is to investigate and fur-
ther delineate the possible molecular pathways that are
modulated in GBM by apigeni. This will provide us with an
insight into the subtypes of GBM that may be susceptible
to apigenin therapy.
Materials and Methods
Cell lines
The GBM cell lines U1242 MG and U87 MG and normal h
astrocytes (NHA) were kindly supplied by Dr Isa M. Hus-
saini (University of Virginia, College of Medicine, Char-
lottesville). These cell lines were originally isolated from
astrocytic tumours and were designated glioblastoma. Their
characteristics were previously described by Hussaini
et al.[26] U1242 MG and U87 MG were maintained in
Modified Eagle’s Medium alpha (MEM-alpha; Gibco,
Carlsbad, CA, USA) supplemented with 10% foetal bovine
serum and 1% penicillin and streptomycin. All cells were
incubated at 37 °C in a humidified atmosphere containing
5% carbon dioxide.
Chemical/biological reagents materials
Apigenin (≥98% purity) and erlotinib were obtained from
Cayman Chemical (Ann Arbor, MI, USA). Phenylmethane-
sulfonyl fluoride (PMSF), sodium orthovanadate, and
Figure 1 Structure of apigenin.
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dimethyl sulfoxide (DMSO), alpha-tubulin, Hoechst 33342
and propidium iodide were purchased from Sigma-Aldrich
(St. Louis, MO, USA). Peroxidase-conjugated affiniPure
goat antirabbit IgG was purchased from Jackson Immu-
noResearch Laboratories (West Grove, PA, USA). Peni-
cillin/Streptomycin antibiotic and MEM-alpha (1X) were
purchased from Gibco. Phospho-EGF receptor, phospho
AKT and phospho-MAP kinase, PARP and Bcl-xL antibod-
ies were purchased from Cell Signaling Technology Inc.
(Danvers, MA, USA). Foetal bovine serum (FBS) was pur-
chased from Biowest LLC (Riverside, MO, USA).
Cell viability and proliferation tests
Membrane integrity and cell viability of U1242 MG and
U87 MG cells were evaluated after treatment with apigenin
(0–80 lM). U1242 MG and U87 MG cells were seeded at a
density of 1 9 105 cells/well in a 6-well plate with or with-
out apigenin for 48 and 72 h. Cells were then harvested and
resuspended in 1 ml of serum free media. 100 ll of cell sus-
pension was stained with 100 ll of 0.4% trypan blue solu-
tion. 20 ll of the cell suspension was placed on to the
haemocytometer and counted. The number of viable and
non-viable cells/ll was determined. Three replicate experi-
ments were performed for each analysis.
The effect of apigenin (0–80 lM) and erlotinib (10 lM)
on cell proliferation was assessed using the MTT (3-(4, 5-
dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide)
assay. Glioblastoma cells were seeded into 96-well plates at
a density of 1 9 104 cells in the presence or absence of
EGF (25 ng/ml). The 96-well plates were then incubated
for 48 and 72 h. After incubation, 20 ll of MTT dye was
added to each well of the 96-well plate, and incubated for
4 h. Finally, 100 ll of stop reagent was added to each well.
The plates were incubated for at least 1 h at room tempera-
ture and then read at a wavelength of 560 nm using the
Promega Glomax multidetection system. The optical den-
sity was used to calculate the rate of cell proliferation after
exposure to different concentrations of apigenin. All exper-
iments were performed in triplicate, and the mean for each
experiment was calculated.
Measurement and detection of cell
apoptosis
A lactate dehydrogenase (LDH) assay was used to deter-
mine cytotoxicity. U1242 MG (1 9 104) cells/well were
cultured in a 96-well plate and allowed to grow overnight.
The next day the cells were treated with apigenin (0–
80 lM) for 72 h per standard protocols. Release of LDH is
an indicator of membrane integrity and hence, cell injury.
The intracellular LDH release was measured at an absor-
bance of 490 nm using a Promega GloMax-Multi
Detection System. The percentage of LDH release was cal-
culated as: (LDH activity in media)/(LDH activity in
media + intracellular LDH activity) 9 100. Each experi-
ment was done independently three times.
Apoptosis staining was performed by using Hoechst
33342. U1242 MG cells were seeded in a 6-well-plate at a
density of 1 9 105 cells/well and treated with various con-
centrations of apigenin (0–80 lM). After 48 h of incuba-
tion, the cells were stained with Hoechst dye (40 mg/ml).
The plates were kept in a dark room for 15 min, which was
followed by the addition of propidium iodide dye to each
well. The plates were left in the dark room for another
15 min. After incubation, the cells were visualised under a
Nikon fluorescence microscope with red and blue filters.
Photomicrographs were taken under a fluorescent phase-
contrast microscope at a magnification of 109 using the
Nikon NIS Elements Imaging Software (version 4.0).
To determine the morphological effects of apigenin on
normal human astrocytes (NHA), NHA cells were grown in
6-well plates and treated with DMSO as control and api-
genin (40 lM) for 48 h. After incubation for 48 h the cells
were imaged using the Nikon NIS Elements Imaging Soft-
ware at a magnification of 109 (version 4.0).
Western blot and protein analysis
Following exposure to different concentrations of apigenin
(0–80 lM), erlotinib (10 lM) and treatment with EGF
(25 ng/ml), the cells were washed with cold phosphate buf-
fered saline (PBS) containing 0.2 mM of sodium orthovana-
date. The cells were lysed with Triton-X-100 lysis buffer
containing 2 mM EDTA, 100 mM NaCl, 0.2% NP-40,
2 mg/ml sodium orthovanadate and 1X protease cocktail
inhibitor. Cells were centrifuged at 16000 9 g for 5 min at
4 °C. Protein concentration was determined using the BCA
assay (Biorad, Hercules, CA, USA). Equal amounts of pro-
tein were boiled for 5 min in 59 sample buffer. Proteins
were separated on 10% SDS-PAGE polyacrylamide gels.
They were then electroblotted onto nitrocellulose mem-
brane. Immunoblotting was performed using either a
mouse monoclonal or rabbit polyclonal primary antibodies
targeting MAPK, AKT, PARP and Bcl-xL. The membranes
were then incubated with HRP-conjugated secondary anti-
body (1 : 2000) at room temperature for 1 h and subse-
quently analysed using the enhanced chemiluminescence
(ECL) reagent (GE Healthcare Life Sciences, Pittsburgh,
PA, USA) and visualised using the Alpha Innotech Flu-
orChem FC2 (Cell Biosciences, Santa Clara, CA, USA).
Flow cytometric analysis of cell cycle arrest
DNA content after treatment with various concentrations
of apigenin (0–80 lM) was used to determine cell cycle
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distribution by propidium iodide (PI). U1242 MG cells
were seeded in 100 mm dishes and cultured for 48 h in the
presence or absence of apigenin. Adherent and floating cells
were collected, centrifuged and washed with PBS. Cells
were then fixed in 1 ml of cold 70% ethanol. After standing
for 16 h at 4 °C, cells were centrifuged and resuspended in
1 ml of DNA staining solution (5 lg/ml PI, 0.1% Triton-X
100, 200 lg/ml of RNase A in PBS). PI-stained cells were
analysed using the Becton Dickinson FACSCalibur, and
data analysis was performed using the Cellquest software.
Figure 2 Effects of apigenin (0–80 lM) on the viability of (a) U1242 MG cells after 48 and 72 h of treatment. (b) Effects of apigenin (0–80 lM) on
the viability of U87 MG cells after 48 and 72 h of treatment. All data are expressed as the mean  SD of experiments performed in triplicate.
*Denotes significant (P < 0.05) difference in cell growth in treated cells compared to untreated control cells. (c) Effects of apigenin (0, 10, 40, 80 lM)
and erlotinib (10 lM) on epidermal growth factor receptor-mediated cell proliferation in U87 MG cells. (d) Effects of apigenin (0, 10, 40, 80 lM) and
erlotinib (10 lM) on epidermal growth factor receptor-mediated cell proliferation in U1242 MG. (e) Effects of apigenin (0, 10, 40, 80 lM) on the mor-
phology of U1242 MG cells (Magnification 910). (f) Cytotoxicity of apigenin (0–80 lM) in U1242 MG cells as measured by a lactate dehydrogenase
assay after 48 and 72 h of treatment. All data are expressed as the mean  SD of experiments performed in triplicate. *Denotes significant
(P < 0.05) difference in cell death in treated cells compared to untreated control cells. [Colour figure can be viewed at wileyonlinelibrary.com]
© 2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, 69 (2017), pp. 907–916910
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Statistical analysis
When indicated, quantitative analysis was conducted using
an analysis of variance (ANOVA) with a Bonferroni post
hoc test (a = 0.05). Statistics were analysed with IBM SPSS
23 (Chicago, IL, USA).
Results
Effects of apigenin on cell viability
To test the effects of apigenin on the viability of GBM cell
lines, we used the trypan blue exclusion assay. The per cent
viability in both the U1242 MG and U87 MG cell lines at
48 and 72 h post-treatment was quantified following expo-
sure to increasing concentrations of apigenin (0–80 lM)
compared with control (DMSO). The effects of apigenin on
U1242 MG and U87 MG cell lines were both concentra-
tion- and time-dependent. As the concentration of apigenin
increased from 0 to 80 lM, the number of cells and per cent
viability decreased (Figure 2a and 2b). Compared to the
untreated control, U1242 MG cells treated with apigenin
showed a significant (P < 0.05) decrease in cell viability
after 48 and 72 h at all concentrations, while the U87 MG
cells were less susceptible to the effects of apigenin at 10 lM
at the 48 h time point (Figure 2b) but were susceptible at
the 72 h period. In addition, we also tested the effects of
erlotinib (10 lM) on EGF-mediated cell proliferation in
GBM cells. We observed a robust inhibition of EGFR-
mediated cell proliferation in the presence of apigenin (10–
80 lM) and erlotinib (10 lM) in U1242 MG and U87 MG
cells (Figure 2c and 2d).
Cytotoxic effects of apigenin
To test the cytotoxic effects of apigenin on GBM cells, we
used the Hoechst-propidium iodide (HO-PI) inclusion/ex-
clusion and LDH cellular level assays. The photomicro-
graphs of Hoechst-PI staining are shown in Figure 2e. In
the U1242 MG cell line, there was an increase in the num-
ber of cells that incorporated PI (nonviable; red cells) as
compared to the cells that incorporated HO (viable; blue
cells). We observed that the number of non-viable cells
increased as the concentration of apigenin increased from
the 0 (control) to concentrations of 10, 40 and 80 lM (Fig-
ure 2e).
The release of a considerable amount of LDH by a cell
signifies a compromised and dying cell. We tested the
effects of apigenin on the release of LDH and measured the
content of LDH in the GBM medium using the LDH assay
kit as described in the experimental section. Apigenin (40–
80 lM) induced a significant cytotoxicity in the U1242
GBM cell line (P < 0.05) at 48 and 72 h (Figure 2f). At
48 h post-treatment, we observed that at the lower concen-
trations of 10 and 20 lM, apigenin showed a cytoprotective
effect by exhibiting a low per cent of LDH release compared
to the control group of cells. Furthermore, we observed that
cells treated with varying concentrations of apigenin for
72 h exhibited an increase in the release of LDH compared
to the untreated control cells. At the 72-h time point, we
no longer observed the initial cytoprotective effect of api-
genin.
Effects of apigenin on apoptotic signalling
Poly ADP-ribose polymerase cleavage and Bcl-xL protein
reduction are standards for the measurement of apoptotic
signalling activation. Their presence also indicates the
Figure 3 (a) Western blot analyses showing the effects of apigenin
(0–80 lM) on the expression of BCL-xL in U1242 MG and U87 MG
cell lines. (b) Western blot analyses showing the effects of apigenin
(0–80 lM) on the cleavage of poly ADP-ribose polymerase in U1242
MG cells.
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activation of pro-apoptotic caspases. In this study, we
tested the effects of apigenin-induced apoptosis in glioblas-
toma cell lines. We investigated the effects of apigenin on
the expression of antiapoptotic proteins Bcl-xL and PARP
cleavage. Treatment with varying concentrations of api-
genin (0–80 lM) in both U1242 MG and U87 MG cells
downregulated the expression of Bcl-xL protein as
measured by Western blot analyses (Figure 3a). Further-
more, we observed that apigenin treatment induces PARP
cleavage in both GBM cell lines. The PARP cleavage
observed was concentration-dependent. The data indicate
that apigenin inhibits the DNA repair mechanism in these
cell lines through the induction of PARP cleavage
(Figure 3b).
Figure 4 (a) Flow cytometry analyses for U1242 MG cells treated with apigenin (0–80 lM). After 72 h, the cells were then stained with propid-
ium iodide and subjected to flow cytometry to analyse the cell cycle distribution. The table (insert) showed the percentage of cells arrested at the
G2/M cell cycle check point. (b) Effects of apigenin (0–80 lM) on the proliferation of U1242 MG cells as measured by a MTT assay after 48 and
72 h of treatment. (c) Effects of apigenin (0–80 lM) on the proliferation of U87 cells as measured by a MTT assay after 48 and 72 h of treatment.
All data are expressed as the mean  SD of experiments. *Denotes significant (P < 0.05) difference in proliferation of treated cells compared to
untreated control cells. [Colour figure can be viewed at wileyonlinelibrary.com]
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Effects of apigenin on glioblastoma cell
cycle and proliferation
To test the effects of apigenin on U1242 MG cell division,
we used flow cytometry to measure how it affects the dif-
ferent phases of cell division. Our analysis showed that
apigenin primarily caused cell cycle arrest at the G2/M
phase of the cell cycle and prevented progression to the
S-phase (Figure 4a). When we compared with vehicle
control cells (57%), with cells treated with apigenin
(20–80 lM) there was an increase in cells arrested at the
G2/M phase (60–67%) at the 72-h time point (see table
insert in Figure 4a).
To further ascertain the effect of apigenin on GBM cell
proliferation, we used the MTT assay. The MTT assay is
widely used to determine the effects of molecules on cell
proliferation. U1242 MG and U87 MG GBM cells grown in
96 well plates were treated with increasing concentrations
of apigenin. Treatment with apigenin (0–80 lM) demon-
strated a concentration-dependent and time-dependent
decrease in cell proliferation. The assay showed a decrease
in the percentage of cells proliferating at each concentration
compared with the control, which was considered 100%
proliferation. The antiproliferative potential of apigenin at
48 and 72 h on the U1242 MG cell is shown (Figure 4b)
and U87 MG cells (Figure 4c). This Figure shows a signifi-
cant (P < 0.05) decrease in cell proliferation compared
with control.
Effects of apigenin on the epidermal
growth factor receptor signalling cascade
To test and ascertain the possible pathways involved in
apigenin-induced decrease in GBM cell proliferation
and apoptosis, we tested its effect on EGFR signalling
because this pathway is paramount and important for
the survival of GBM. Also, apigenin has been shown to
affect EGFR signalling in head and neck tumours. To
test the effects of apigenin and erlotinib (10 lM) on
EGFR-mediated signalling in GBM cells, we pretreated
U1242 MG and U87 MG cells with apigenin (0–80 lM)
and erlotinib (10 lM) and these cells were then treated
Figure 5 (a) Western blot analyses showing the effects of apigenin (0–80 lM) and erlotinib (10 lM) on EGF-induced phosphorylation of AKT in
U87 and U1242 MG cell lines. (b) Western blot analyses showing the effects of apigenin (0–80 lM) and erlotinib (10 lM) on EGF-induced phos-
phorylation of ERK1/2 in U87 and U1242 MG cell lines. (c) Western blot analyses showing the effects of apigenin (0–80 lM) on EGF-induced phos-
phorylation of mammalian target of rapamycin in U87 and U1242 MG cell lines. (d) Western blot analyses showing the effects of apigenin (0–
80 lM) on EGF-induced phosphorylation of ribosomal protein 70S6 kinase (pS6K) phosphorylation in U87 and U1242 MG cell lines.
© 2017 Royal Pharmaceutical Society, Journal of Pharmacy and Pharmacology, 69 (2017), pp. 907–916 913
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with EGF (25 ng/ml) for 15 min. Cell lysates were blot-
ted using Western blot analysis for growth signalling
molecules, such as phosphorylated AKT, phosphorylated
ERK, mTOR and S6K, that are known pathways down-
stream of EGFR activation. Western blot analyses
showed apigenin caused a concentration-dependent
decrease in AKT phosphorylation in both cell lines sim-
ilar to the effects of erlotinib in the presence of EGF
treatment (Figure 5a). Similarly, we observed a decrease
in the phosphorylated levels of ERK in U1242 MG cells
following apigenin and erlotinib treatments (Figure 5b).
ERK phosphorylation in the U87 MG cells was not sig-
nificantly perturbed by treatment with apigenin com-
pared with erlotinib (Figure 5b). Furthermore, we tested
the effects of apigenin pretreatment on mTOR and
S6K. We report here that treatment with apigenin
downregulated the phosphorylation levels of mTOR
(Figure 5c) and S6K (Figure 5d) in both cell lines in
the presence of EGF. Overall, the data revealed that
apigenin attenuated phosphorylated levels of AKT,
mTOR and S6K in both cell lines. This data therefore,
suggests a more robust inhibition of the AKT-mTOR
signalling pathways as compared to the ERK-MAPK sig-
nalling pathways.
Effects of apigenin on normal human
astrocytes
Finally, we tested the effects of apigenin on the morphology
of NHA cells. NHA cells grown to about 60% confluency
were treated with DMSO control and apigenin (40 lM) for
48 h. At the 48-h time point, the morphological photomi-
crograph of the cells was taken using the Nikon NIS Ele-
ment Imaging software (version 4.0). We did not observe
any morphological change in cells treated with apigenin
compared with the control cells, suggesting that apigenin
had a more pronounced biological activity in cancer cells
(Figure 6).
Discussion
Glioblastoma presents with a variety of therapeutic chal-
lenges due to its heterogeneity, invasiveness and resistance
to apoptosis.[5, 27, 28] These effects are promoted by EGFR
amplifications, which are the most common oncogenic
mutations in GBM.[7] Such amplifications are key to the
pathogenesis of GBM and thus present an important target
for therapy. Apigenin demonstrated marked inhibition of
GBM cells treated with 25 ng/ml EGF. These in-vitro results
demonstrate the promising antitumour activity of apigenin
through EGFR signalling inhibition. Our data in Figure 6
showed that apigenin, at the dose tested did not produce
any morphological change in the treated NHA cells and
untreated control NHA cells. Through cell counts, MTT
assays, LDH assays and Hoechst-propidium iodide stain-
ing, apigenin displayed its biological relevance as a poten-
tial therapeutic agent for cancer treatment. Apigenin
inhibited cellular growth and proliferation in both a dose-
and time-dependent manner. This confirms previous
results that demonstrate the therapeutic utility of apigenin
in other cancers.[19–23,29] Of particularly importance, api-
genin inhibited downstream targets of EGFR signalling as
demonstrated by inhibition of AKT phosphorylation as well
as S6K and mTOR in both cell lines. Activation of the
PI3K/AKT pathway through phosphorylation induces cell
growth, proliferation and inhibits apoptosis possibly by
blocking the effects of pro-apoptotic targets such as Bad
and activating pro-survival transcription factor NF-
jB.[18,30]
Apigenin inhibited ERK phosphorylation in the U1242
cell line but did not modulate ERK phosphorylation in U87
cells. Phosphorylated ERK enhances cell growth, prolifera-
tion, differentiation and migration.[31] We observed a
robust, more pronounced effects of erlotinib on both AKT
and ERK signalling pathways. Taken together, our data on
EGFR-mediated signalling could suggest that the biological
effect of apigenin on glioblastoma growth may be mediated
via the AKT/mTOR signalling. Through these mechanisms,
Figure 6 Effects of apigenin (40 lM) on the morphology of normal
human astrocytes.
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apigenin impacted key characteristic signalling molecules
mediating EGFR-induced cell proliferation and resistance
to apoptosis in both cell lines. This resulted in a decrease in
tumour cell viability demonstrated in cell counts, cell pro-
liferation and apoptotic signalling molecules. These effects
demonstrate the potential of apigenin to inhibit GBM
tumour progression in vitro.
Beyond the effects on the EGFR signalling cascade, api-
genin also impacted certain antiapoptotic markers such as
Bcl-xL and PARP.[32] Apigenin inhibited Bcl-xL in both cell
lines suggesting the possible involvement of cytochrome C
and caspase-9 activation in apigenin-induced GBM apopto-
sis.[32] PARP cleavage results in a loss of the DNA repair
function.[33] We showed marked increase in PARP cleavage
at 40 and 80 lM indicating a loss of DNA repair and G2/M
cell cycle arrest. We observed a G2/M phase cell cycle arrest
with flow cytometry confirming the effect of apigenin on
PARP inactivation. Apigenin demonstrated protective effects
in the U1242 cell line at lower concentrations in the LDH
assays. These protective effects have been demonstrated with
other flavonoids and have been hypothesised to be due to
antioxidant properties. Additionally, the increase in cleaved
PARP shown at higher concentrations of apigenin may play
a role in eliminating the protective effects. At the 10 and
20 lM concentrations apigenin did not increase PARP cleav-
age, but at both the 40 and 80 lM concentrations it caused a
marked increase in cleaved PARP. This loss of DNA repair
could be fundamental in the mechanism for inducing apop-
tosis at the G2/M checkpoint.
Conclusion
These results provide a picture of the chemotherapeutic
potential of apigenin. Our results demonstrate the ability of
apigenin to not only inhibit cellular growth and prolifera-
tion, but also induce apoptosis in GBM cells. Apigenin
markedly inhibited EGFR signalling, which is key to the
pathogenesis of GBM.[34,35] Overall, apigenin provides
effective tumour suppression through blockade of down-
stream targets of the EGFR pathway.
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